Ginkgo Bioworks (US:DNA) ZACKSยท2025-04-23 23:21Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $7.60, reflecting a +0.8% change from the previous day, underperforming the S&P 500 which gained 1.67% [1] - Over the past month, the company's shares increased by 5.9%, while the Medical sector and S&P 500 saw declines of 9.34% and 6.57% respectively [1] Upcoming Earnings - The upcoming earnings release is expected to show an EPS of -$1.23, a 61.56% increase compared to the same quarter last year [2] - Revenue is anticipated to be $41.26 million, indicating an 8.74% increase from the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$3.72 per share, representing a +64.09% change from the prior year, while revenue is expected to be $171.48 million, reflecting a -24.47% change [3] Analyst Estimates - Recent changes to analyst estimates indicate confidence in the company's business performance and profit potential [4] - The Zacks Rank system, which assesses estimate changes, currently ranks Ginkgo Bioworks Holdings, Inc. at 2 (Buy) [6] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - Research indicates that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]